Regenerative Medical Solutions (RMS) is a privately-owned company based in Madison, Wisconsin and Chicago, Illinois. With a team of experts in stem cell research, RMS has made groundbreaking scientific breakthroughs in the field. Their focus lies in the development and application of stem cell derived Islet-Like Clusters (ILC) for drug discovery and therapeutic purposes in combating diabetes, a global health concern affecting millions of people.

RMS has extensive experience in stem cell development, pancreatic islet biology, and islet transplantation. In addition, their broad business experience and track record of entrepreneurship, product development, and strategic growth have established them as a trusted partner in the industry. Collaborating with researchers at the University of Wisconsin Madison, national pharmaceutical companies, and international biotech companies, RMS aims to find a cure for diabetes.

Their advanced research facility produces human induced pluripotent stem cell derived ILCs with a strong IP portfolio comprising granted and pending patents. At the helm of RMS is a distinguished leadership team led by Anthony Kolton as President and CEO, along with renowned scientist and co-founder Dr. Jon Odorico, M.

D., F. A. C.

S. Regenerative Medical Solutions is dedicated to revolutionizing the field of regenerative medicine and transforming the lives of those affected by diabetes